These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 26272690)
1. Use of Hormone Testing for the Diagnosis and Evaluation of Male Hypogonadism and Monitoring of Testosterone Therapy: Application of Hormone Testing Guideline Recommendations in Clinical Practice. Muram D; Zhang X; Cui Z; Matsumoto AM J Sex Med; 2015 Sep; 12(9):1886-94. PubMed ID: 26272690 [TBL] [Abstract][Full Text] [Related]
2. Testosterone and gonadotropin levels in men with dementia. Hogervorst E; Combrinck M; Smith AD Neuro Endocrinol Lett; 2003; 24(3-4):203-8. PubMed ID: 14523358 [TBL] [Abstract][Full Text] [Related]
3. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update. Petak SM; Nankin HR; Spark RF; Swerdloff RS; Rodriguez-Rigau LJ; Endocr Pract; 2002; 8(6):440-56. PubMed ID: 15260010 [TBL] [Abstract][Full Text] [Related]
4. Male hypogonadotropic hypogonadism: factors influencing response to human chorionic gonadotropin and human menopausal gonadotropin, including prior exogenous androgens. Ley SB; Leonard JM J Clin Endocrinol Metab; 1985 Oct; 61(4):746-52. PubMed ID: 3928676 [TBL] [Abstract][Full Text] [Related]
5. Critical evaluation of different available guidelines for late-onset hypogonadism. Giagulli VA; Castellana M; Lisco G; Triggiani V Andrology; 2020 Nov; 8(6):1628-1641. PubMed ID: 32593233 [TBL] [Abstract][Full Text] [Related]
6. Hypogonadotropic eunuchoidism. II. Gonadal responsiveness to exogenous gonadotropins. Santen RJ; Paulsen CA J Clin Endocrinol Metab; 1973 Jan; 36(1):55-63. PubMed ID: 4404633 [No Abstract] [Full Text] [Related]
7. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels. Blick G Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769 [TBL] [Abstract][Full Text] [Related]
8. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations. Wallace EM; Gow SM; Wu FC J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955 [TBL] [Abstract][Full Text] [Related]
9. Effects of depot testosterone therapy on serum levels of luteinizing hormone and follicle-stimulating hormone in patients with Klinefelter's syndrome and hypogonadotropic eunuchoidism. Fukutani K; Isurugi K; Takayasu H; Wakabayashi K; Tamaoki B J Clin Endocrinol Metab; 1974 Nov; 39(5):856-64. PubMed ID: 4418679 [No Abstract] [Full Text] [Related]
10. A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism. Kaminetsky JC; Moclair B; Hemani M; Sand M J Sex Med; 2011 Apr; 8(4):1186-96. PubMed ID: 21269402 [TBL] [Abstract][Full Text] [Related]
11. Normal adults and subjects with hypogonadotropic hypogonadism respond differently to D-Ser(TBU)6-LH-RH-EA10. Smith R; Donald RA; Espiner EA; Stronach SG; Edwards IA J Clin Endocrinol Metab; 1979 Jan; 48(1):167-70. PubMed ID: 106067 [TBL] [Abstract][Full Text] [Related]
12. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. Matsumoto AM J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626 [TBL] [Abstract][Full Text] [Related]
13. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost. Taylor F; Levine L J Sex Med; 2010 Jan; 7(1 Pt 1):269-76. PubMed ID: 19694928 [TBL] [Abstract][Full Text] [Related]
14. Late-onset hypogonadism: a concept comes of age. Nieschlag E Andrology; 2020 Nov; 8(6):1506-1511. PubMed ID: 31639279 [TBL] [Abstract][Full Text] [Related]
15. Enclomiphene citrate for the treatment of secondary male hypogonadism. Rodriguez KM; Pastuszak AW; Lipshultz LI Expert Opin Pharmacother; 2016 Aug; 17(11):1561-7. PubMed ID: 27337642 [TBL] [Abstract][Full Text] [Related]
16. Serum inhibin concentrations before and during gonadotropin treatment in men with hypogonadotropic hypogonadism: physiological and clinical implications. McLachlan RI; Finkel DM; Bremner WJ; Snyder PJ J Clin Endocrinol Metab; 1990 May; 70(5):1414-9. PubMed ID: 2110576 [TBL] [Abstract][Full Text] [Related]
17. EAA clinical practice guidelines-gynecomastia evaluation and management. Kanakis GA; Nordkap L; Bang AK; Calogero AE; Bártfai G; Corona G; Forti G; Toppari J; Goulis DG; Jørgensen N Andrology; 2019 Nov; 7(6):778-793. PubMed ID: 31099174 [TBL] [Abstract][Full Text] [Related]
18. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism. Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803 [TBL] [Abstract][Full Text] [Related]
19. Testosterone Therapy and Risk of Acute Myocardial Infarction in Hypogonadal Men: An Administrative Health Care Claims Study. Li H; Mitchell L; Zhang X; Heiselman D; Motsko S J Sex Med; 2017 Nov; 14(11):1307-1317. PubMed ID: 29110802 [TBL] [Abstract][Full Text] [Related]
20. Canadian Society for the Study of the Aging Male: response to health Canada's position paper on testosterone treatment. Bain J; Brock G; Kuzmarov I; For The International Consulting Group J Sex Med; 2007 May; 4(3):558-566. PubMed ID: 17498097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]